Global Age-Related Macular Degeneration (AMD) Disease Market is expected to grow with the CAGR of 8.3% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-age-related-macular-degeneration-amd-disease-market

Global age-related macular degeneration (AMD) disease market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global age-related macular degeneration (AMD) disease market are introducing strong range of product providers along with launching new services and adopting strategic initiative such as acquisition, agreement, business expansion, awards and recognition into the market. This helped the companies to maximize the sales with enhanced service portfolio.

• In April 2022, Graybug Vision Inc. announced that the company had presented preclinical data poster at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and drug evaluation in the market.
• In January 2022, Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo (faricimab-svoa) to treat wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.

Novartis AG is the dominating player in the market. The other key players existing in the market includes Genentech Inc., Bayer AG, PIXIUM VISION, Astellas Pharma Inc., REGENXBIO Inc., Ionis Pharmaceutics, Ocugen Inc, Johnson & Johnson Services, Inc, IVERIC bio, MeiraGTx Limited, Gensight Biologics, Adverum Biotechnologies, Inc., Graybug Vision Inc., Kodiak Sciences Inc., among others.

NOVARTIS AG

Novartis AG is headquartered in Basel, Switzerland and founded in the year 1996. The company offers cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, Neuroscience, and Respiratory as a product category and Ophthalmology as the market-focused category. The company has presence in North America, South America, Europe, Asia-Pacific, Middle East and Africa.

• In 2018, Novartis AG entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for Luxturna outside the United States. The agreements include regulatory and sales milestones as well as royalty’s payable to Spark on ex-US sales. This will allow for the sales of luxturna to increase.

The company has various subsidiaries that are Novartis Argentina S.A., Buenos Aires(Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde (Belgium), Sandoz (China) Pharmaceutical (China) among others.

GENENTECH INC.

Genentech Inc. is headquartered in California, U.S. was founded in the year 1976. The company offers biooncology, immunology and ophthalmology, metabolism & primary care, neurology, virology & specialty care and other products as a product category and immunology and ophthalmology as the market-focused category. The company has presence in North America.

In January 2022, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo (faricimab-svoa) to treat wet AMD and DME. This will help in expanding the product portfolio of the company.The company has various subsidiaries that are Tanox, Piramed Limited, Genentech USA, Inc. and among others.

BAYER AG

Bayer AG is headquartered in Germany founded in year 1863. The company is focused on innovation and sustainability through making the world healthier by accelerating life science research, solving complex analytical challenges and improving patients therapies and diagnostics for patients around the world for Cardiology, women’s healthcare, oncology, hematology, ophthalmology, over-the-counter in dermatology, nutritional supplement, analgesic, digestive health, cold, allergy, sinus and flu as a product category and Ophthalmology as the market-focused category.

• In October 2020, Bayer acquired Asklepios BioPharmaceutical. A company focused on innovating new solutions targeting the neuromuscular, central nervous system, and respiratory. This initiative allowed the company to boost up the company’s product portfolio and fulfil the unmet patient demands that have accelerated the company’s overall growth.

The company has a presence in the North America, Europe, Asia-Pacific, South America, Middle East and Africa. The company has various subsidiaries that are AgrEvo Verwaltungsgesellschaft mbH (Frankfurt), Alcafleu Management GmbH & Co. KG (Germany) AO Bayer (Moscow), Bayer (Proprietary) Limited Isando( South Africa), Bayer (Schweiz) AG Zurich, (Switzerland) among other.